Floatz logo

Nktr-214

HR+/HER2- Breast Cancer

Nektar TherapeuticsPhase 1/2Dormant
CCC
48/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
37/ 100
Competitive Position
81/ 100

Competitive context

117 Active assets in the HR+/HER2- Breast Cancer cohort.

Asset / SponsorPhaseRating
Everolimus
Ellipses Pharma
Phase 4BBB
EXEMESTANE
Fujian Cancer Hospital
Phase 4BBB
Arimidex
University of Illinois at Chicago
Phase 4BBB
Ribociclib
BeOne Medicines
Phase 4BBB
Palbociclib
BeOne Medicines
Phase 3BBB

View all 50 →

Same molecule, other indications

Nktr-214 is also rated in:

urothelial carcinomaDormant
CC
Indicative ·
46 / 100
View asset →
melanomaDormant
CC
Indicative ·
44 / 100
View asset →
renal cell carcinomaDormant
CC
Indicative ·
44 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →